AVEO Oncology (AVEO) has a couple of catalysts coming its way this year.
A pre-planned interim futility analysis of phase III trial comparing investigational drug Tivozanib to approved drug Nexavar (sorafenib) in subjects with refractory advanced renal cell carcinoma, dubbed TIVO-3, is expected around mid-year 2017.
Enrollment in the TIVO-3 trial is anticipated to be completed in June 2017, ahead of its prior guidance of August 2017. Top line data from the trial is expected in the first quarter of 2018.
A Phase 1/2 trial evaluating Tivozanib in combination with Bristol-Myers Squibb’s (BMY) Opdivo in advanced renal cell carcinoma, known as TiNivo, is underway. The Phase 1 portion of the trial is expected to be completed in the first half of 2017.
In Europe, Tivozanib is under review by the European Medicines Agency. The Marketing Authorisation Application for Tivozanib was submitted to the European Medicines Agency by AVEO’s partner EUSA Pharma.